Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
New induction (Ind), gemcitabine (G), docetaxel (D) and cisplatin (C) followed by concomitant (Con) chemoradiotherapy in stage IIIB non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008
The role of serum cathepsin S levels in sarcoidosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
The role of cathepsin D, H & K in the regulation of tumstatin levels in asthmatic airways Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011
Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Changes in the expression of Glutathione S Transferase-π (GST-π) and P-glycoprotein (P-gp) in bronchoscopic specimen of patients with lung cancer before and after chemotherapy Source: Eur Respir J 2001; 18: Suppl. 33, 231s Year: 2001
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
The role of cathepsin S in lung disease Source: International Congress 2018 – Proteases: at the cutting edge of lung disease Year: 2018
A serum level of IGF-I, IGF-II and IGFBP-3 in patients with small cell lung cancer (SCLC) during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 86s Year: 2006
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
Evaluation of serum levels of Sirtuin-1 in lung cancer patients Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Clinical significance of serum survivin, MGB-1 and Pref-1 levels during chemotherapy of lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Correlation between change in lung density and lung function parameters in treated alpha-1 protease inhibitor (A1-PI) deficiency Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016
Carboplatin (C), paclitaxel (T) and etoposide (E) and early concurrent thoracic radiotherapy (TRT) for patients with limited disease small cell lung cancer (LD-SCLC): a Dutch multicentre phase 2 study Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002